Abstract: A method is provided of regulating transcription in a plant cell from a DNA sequence comprising a target DNA operably linked to a coding sequence, which method comprises introducing an engineered zinc finger polypeptide in said plant cell which polypeptide binds to the target DNA and modulates transcription of the coding sequence.
Type:
Grant
Filed:
September 12, 2007
Date of Patent:
April 21, 2009
Assignees:
Gendaq Limited, The Rockfeller University
Inventors:
Yen Choo, Christopher Graeme Ullman, Nam-Hai Chua, Juan Pablo Sanchez
Abstract: Attenuated influenza virus variants comprising substitutions in NS1 that interfere with viral replication and phosphatidylinositol 3-kinase activation are described. NS1 variant polypeptides, polynucleotides encoding NS1 variant polypeptides, a reverse genetics system for producing attenuated influenza virus NS1 variants, immunogenic compositions comprising live attenuated influenza virus NS1 variants, methods of stimulating an immune response against influenza virus, methods of interfering with influenza virus replication, and methods of treating and preventing influenza virus infection are described.
Type:
Grant
Filed:
June 11, 2007
Date of Patent:
March 24, 2009
Assignee:
University of Saskatchewan
Inventors:
Yan Zhou, Yeun-Kyung Shin, Lorne A. Babiuk, Qiang Liu
Abstract: Mosaic VLPs of viral capsid proteins from different virus types are described, as are methods of making the same. Specifically, a diploid yeast strain that coexpresses the L1 and L2 capsid proteins of both HPV-6 and HPV-16 as mosaic VLPs is described. The mosaic VLPs induced the production of conformational antibodies against both L1 proteins upon administration to mice.
Type:
Grant
Filed:
April 13, 2006
Date of Patent:
February 24, 2009
Assignee:
Novartis Vaccines and Diagnostics, Inc.
Inventors:
Daniela Tornese Buonamassa, Catherine E. Greer, Cesira L. Galeotti, Giuliano Bensi, Roberto Petracca
Abstract: The present invention relates to methods of using libraries of randomized zinc finger proteins to identify genes associated with selected phenotypes.
Type:
Grant
Filed:
January 6, 2003
Date of Patent:
February 17, 2009
Assignee:
Sangamo BioSciences, Inc.
Inventors:
Casey C. Case, Edward J. Rebar, Andrew Jamieson
Abstract: Accessory functions capable of supporting efficient recombinant AAV (rAAV) virion production in a suitable host cell are provided. The accessory functions are in the form of one or more vectors that are capable of being transferred between cells. Methods of producing rAAV virions are also provided. The methods can be practiced to produce commercially significant levels of rAAV particles without also generating significant levels of infectious helper virus or other contaminating by-products.
Abstract: The present invention relates generally to carrier molecules derived from one animal or avian species or strains and which are substantially non-immunogenic when exposed to an immune system from a species or strain of another animal or avian creature. More particularly, the present invention provides deimmunized immunointeractive molecules and even more particular deimmunized antibodies for use in diagnostic and therapeutic applications.
Abstract: The present invention relates to transcription control elements derived from mouse and human genes associated with cytochrome expression, e.g., Cyp3A11 and CYP3A4, respectively. Isolated polynucleotides, expression cassettes, vectors, recombinant cells, and transgenic animals, may comprise such transcription control elements as described herein.
Type:
Grant
Filed:
April 11, 2002
Date of Patent:
November 11, 2008
Assignee:
Xenogen Corporation
Inventors:
Weisheng Zhang, Pamela Contag, Anthony Purchio, Sandy Hashima, Shirley Ma, Kevin Nawotka
Abstract: The present invention relates to panels of reporter expression cassettes and the generation of transgenic non-human animals, wherein said reporter expression cassettes have selected control elements operable linked to reporter genes. The invention includes methods of use thereof for the identification and characterization of the effects of compounds administered to the live transgenic non-human animals.
Abstract: Polypeptides comprising a mutant non-structural Hepatitis C virus useful in diagnostic and/or immunogenic compositions are disclosed, in which the mutant is an N-terminal mutation that functionally disrupts the catalytic domain of NS3. Polynucleotides encoding these polypeptides, host cells transformed with polynucleotides and methods of using the polypeptides and polynucleotides are also disclosed.
Type:
Grant
Filed:
August 2, 2005
Date of Patent:
November 11, 2008
Assignee:
Novartis Vaccines and Diagnostics, Inc.
Inventors:
Doris Coit, Angelica Medina-Selby, Mark Selby, Michael Houghton
Abstract: The invention relates to pharmaceutical compositions comprising gastrointestinal proliferative factor SCFA2, SCFA4 or SCFA4v polynucleotides and polypeptides. The invention further relates to the therapeutic use of SCFA2, SCFA4 or SCFA4v to prevent or treat conditions or disorders associated with the degeneration of the epithelial mucosa.
Type:
Grant
Filed:
January 17, 2006
Date of Patent:
October 21, 2008
Assignee:
Nuvelo, Inc.
Inventors:
Bryan J. Boyle, Peter C. R. Emtage, Walter Funk, Y. Tom Tang, Jingsong Zhao
Abstract: Methods for obtaining recombinantly produced, C-terminally truncated, E1 and E2 polypeptides from cell lysates are disclosed. The intracellularly expressed truncated molecules display improved biological properties as compared to their secreted counterparts.
Type:
Grant
Filed:
February 18, 2003
Date of Patent:
September 30, 2008
Assignee:
Novartis Vaccines & Diagnostics
Inventors:
Michael Houghton, Qui-Lim Choo, Sergio Abrignani, David Chien, Mark Selby, Edward Glazer
Abstract: Methods of making and using recombinant AAV vectors and virions for gene delivery to the lung are described. The recombinant AAV virions are derived from caprine AAV and bovine AAV, both of which display tropism for lung tissue.
Type:
Grant
Filed:
June 2, 2005
Date of Patent:
September 23, 2008
Assignee:
Genzyme Corporation
Inventors:
Alejandra E. Arbetman, Michael A. Lochrie
Abstract: The invention provides novel polynucleotides and polypeptides encoded by such polynucleotides and mutants or variants thereof that correspond to a novel human secreted stem cell growth factor-like polypeptides. Other aspects of the invention include vectors containing processes for producing novel human secreted stem cell growth factor-like polypeptides, and antibodies specific for such polypeptides.
Abstract: The present invention provides methods and compositions for interaction trap assays for detecting protein-protein, protein-DNA, or protein-RNA interactions. The methods and compositions of the invention may also be used to identify agents which may agonize or antagonize a protein-protein, protein-DNA, or protein-RNA interaction. In certain embodiments, the interaction trap system of the invention is useful for screening libraries with greater than 107 members. In other embodiments, the interaction trap system of the invention is used in conjunction with flow cytometry. The invention further provides a means for simultaneously screening a target protein or nucleic acid sequence for the ability to interact with two or more test proteins or nucleic acids.
Type:
Grant
Filed:
March 16, 2004
Date of Patent:
July 1, 2008
Assignee:
Massachusetts Institute of Technology
Inventors:
J. Keith Joung, Jeffrey Miller, Carl O. Pabo
Abstract: The invention relates to a method for producing an addition salt of 2,4?-dimethyl-3-piperidino-propiophenone (tolperisone) with a pharmaceutically acceptable acid, of formula (I).
Type:
Grant
Filed:
March 31, 2003
Date of Patent:
June 10, 2008
Assignee:
Sanochemia Pharmazeutika AG
Inventors:
Laszlo Czollner, Beate Kälz, Jan Rothenburger, Stefan Welzig
Abstract: The hypervariable region (E2HV) of the putative hepatitis C virus (HCV) glycoprotein E2/NS1, between about amino acid 384 to about amino acid 414, is a rapidly evolving region of HCV, and is likely to be under positive immune selection. A newly discovered motif within this hypervariable region is immunogenic and conserved with respect to the character of the amino acids. In many isolates, this motif falls between amino acids 401 to 406 or 407. The discovery of this motif allows for additional materials and methods to treat and diagnose HCV.
Abstract: Disclosed herein are methods and compositions for treatment of conditions requiring inhibition of angiogenesis. Such conditions include those characterized by neovascularization, such as retinopathies, macular degeneration and various malignancies.
Abstract: A highly concentrated, low salt-containing, biologically active syrup form of IGF-I or variant thereof and methods for its preparation are provided. This novel syrup form of IGF-I has an IGF-I concentration of at least about 250 mg/ml, a density of about 1.0 g/ml to about 1.2 g/ml, and a viscosity of about 13,000 centipoise (cps) to about 19,000 cps, as measured at ambient temperature (23° C.). The IGF-I syrup is prepared by precipitating or partitioning IGF-I from solution, preferably by adjusting the solution pH or by use of a solubility enhancer to concentrate IGF-I in solution followed by removal of the solubility enhancer. The precipitated syrup is useful as a means of storing IGF-I in a stable form and as a means of preparing compositions comprising biologically active IGF-I. Pharmaceutical compositions and kits comprising this concentrated IGF-I syrup are provided.